Your shopping cart is currently empty

Axl-IN-17 (compound 13c) is an orally active and selective AXL inhibitor with an IC50 value of 3.0 nM, demonstrating antitumor activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Axl-IN-17 (compound 13c) is an orally active and selective AXL inhibitor with an IC50 value of 3.0 nM, demonstrating antitumor activity. |
| In vitro | Axl-IN-17 inhibits multiple kinases, including TYRO3, MER, MET, and RON, at a concentration of 1 μM. In BaF3/TEL-AXL cells, it demonstrates antiproliferative activity with an IC50 value of less than 1 nM. Axl-IN-17 (1 nM, 2 h) also suppresses AXL phosphorylation and its downstream signaling pathways. |
| In vivo | Axl-IN-17 (oral, 3 mg/kg, once daily) exhibits favorable pharmacokinetic properties, with a half-life of 10.09 hours and an AUC value of 59815 ng•h/mL. Axl-IN-17 (p.o., 25, 50, 100 mg/kg, once daily, for seven days) shows anti-tumor effects in AXL-driven tumor xenograft mice. |
| Molecular Weight | 563.60 |
| Formula | C32H27F2N7O |
| Cas No. | 3048409-80-6 |
| Smiles | O=C1C(=CN(C=2C=CN=C(NC=3C=CC(=C(F)C3)C=4C=C(C=NC4N)C=5C=NN(C5)C)C12)C(C)C)C=6C=CC(F)=CC6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.